Alec Machiels - 15 Mar 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Alec Machiels
Issuer symbol
APLS
Transactions as of
15 Mar 2022
Net transactions value
-$46,125
Form type
4
Filing time
17 Mar 2022, 20:59:38 UTC
Previous filing
16 Feb 2022
Next filing
18 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $3,338 +1,250 +0.48% $2.67* 260,794 15 Mar 2022 Direct F1
transaction APLS Common Stock Sale $49,462 -1,250 -0.48% $39.57 259,544 15 Mar 2022 Direct F1
holding APLS Common Stock 250,000 15 Mar 2022 See footnote F2
holding APLS Common Stock 11,950 15 Mar 2022 See footnote F3
holding APLS Common Stock 150,000 15 Mar 2022 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock option (right to buy) Options Exercise $0 -1,250 -0.99% $0.000000 124,779 15 Mar 2022 Common Stock 1,250 $2.67 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 where effected pursuant to a written Rule 10b5-1 trading plan adopted by the reported person.
F2 The shares are held by Bauhaus 1 LLC, which LLC is held by The Irrevocable Agreement of Trust of Alec Machiels (the "Trust"). The reporting person is the managing member of Bauhaus 1 LLC and the trustee of the Trust.
F3 Owned by the spouse of the reporting person.
F4 Owned by a trust of which the reporting person is the trustee.
F5 This option was granted on December 5, 2013 and is fully vested.